ofd1 Antibody

What is OFD1 protein and what cellular structures is it associated with?

OFD1 (Oral-Facial-Digital Syndrome 1) is a centrosomal protein with multiple cellular localizations and functions. In humans, the canonical OFD1 protein consists of 1012 amino acid residues with a molecular mass of approximately 116.7 kDa. This protein is a key component of the centrioles, specifically controlling the length of both mother and daughter centrioles. OFD1 shows subcellular localization in both the nucleus and cytoplasm, with strong enrichment at the basal body of primary cilia . Confocal microscopy studies using anti-OFD1 antibodies have confirmed that the protein localizes specifically at the base of primary cilia in MDCK cells cultured under conditions promoting ciliogenesis, but is not detected in the ciliary axoneme itself . The protein is widely expressed across numerous tissue types, making it relevant for studying various developmental and disease processes.

What are the established applications for OFD1 antibodies in research?

OFD1 antibodies have proven valuable across multiple experimental applications in the research setting. Western blotting represents one of the most common applications, allowing researchers to detect both endogenous and overexpressed OFD1 protein from cell and tissue lysates . Immunohistochemistry, particularly on paraffin-embedded tissue sections (IHC-p), is another widely utilized application for studying OFD1 expression patterns in different tissues . Immunofluorescence microscopy has been instrumental in determining OFD1's subcellular localization, particularly its presence at centrosomes, basal bodies, and within nuclei . Additionally, immunoprecipitation experiments have successfully employed anti-OFD1 antibodies to study protein-protein interactions, revealing OFD1's association with proteins like RuvBl1 and components of the TIP60 histone acetyltransferase complex .

What disease associations make OFD1 a target of research interest?

OFD1 gained significant research interest after being identified as the gene responsible for Oral-facial-digital (OFD) type I syndrome, an X-linked dominant disease (MIM311200) . This genetic disorder is characterized by malformations of the oral cavity, face, and digits, along with the development of cystic kidneys . More recently, OFD1 has been linked to additional ciliopathies and ciliary functions, highlighting its importance in human developmental biology and disease. Researchers utilize OFD1 antibodies to investigate the molecular mechanisms underlying these disorders, particularly focusing on how alterations in OFD1 expression or localization might contribute to disease pathogenesis.

What are the key considerations when selecting an anti-OFD1 antibody for research?

When selecting an anti-OFD1 antibody, researchers should evaluate several critical factors to ensure experimental success. First, consider the epitope recognition—anti-OFD1 antibodies may target different regions of the protein, such as C-terminal domains (like the anti-OFD1 Cter targeting residues 996-1011) or central regions (like anti-OFD1 cent targeting residues 351-364) . These different epitope targets may influence detection capabilities, particularly if studying specific OFD1 isoforms or truncated variants.

Second, species reactivity is crucial—many commercial antibodies demonstrate reactivity against human, mouse, and rat OFD1 orthologs, but cross-reactivity should be verified experimentally for your model system . Third, consider the available conjugations—while unconjugated primary antibodies are most common, specialized applications may benefit from directly conjugated antibodies (biotin, fluorophores) .

Finally, validation evidence is essential—prioritize antibodies with published citations, particularly those demonstrating successful use in your intended application (Western blot, immunohistochemistry, etc.) .

How can researchers optimize immunoprecipitation protocols for OFD1 protein interaction studies?

Optimizing immunoprecipitation (IP) protocols for OFD1 requires careful consideration of several parameters based on published methodologies:

• Lysis buffer composition: For OFD1 co-IP experiments, buffers containing 10 mM Tris HCl (pH 7.5), 150 mM NaCl, and 1% Triton X-100, supplemented with protease inhibitors have been successfully employed for studying OFD1 self-association . For investigations of OFD1 interactions with nuclear components like RuvBl1 or TIP60 complex components, buffers containing 50 mM Tris (pH 7.9), 0.1% Tween 20, 1% Triton, 150 mM NaCl, and 5 mM MgCl2 have proven effective .

• Antibody selection: For endogenous OFD1 immunoprecipitation, polyclonal antibodies targeting the C-terminus (e.g., anti-OFD1 Cter) have been successfully used at dilutions of approximately 1:60 for IP applications . For overexpressed tagged versions of OFD1, anti-tag antibodies (anti-Myc at 1:100, anti-Flag M2 at 1:100) have shown good efficiency .

• Elution strategies: When studying endogenous OFD1 interactions, specific peptide elution can be utilized to minimize background and increase specificity. For example, immunocomplexes can be eluted with the OFD1 peptide KVESLTGFSHEELDDSW, which corresponds to the C-terminal epitope .

• Controls: Appropriate controls are essential, including IP with preimmune serum or IgG matched to the primary antibody host species, and cell lysates expressing single components when studying multiple protein interactions .

What approaches are recommended for visualizing OFD1 localization in ciliated cells?

Visualizing OFD1 in ciliated cells requires specialized approaches to accurately distinguish between its multiple subcellular localizations. Confocal microscopy represents the gold standard for this application, allowing researchers to resolve OFD1's presence at the basal body from its nuclear localization .

For optimal results, cells should be cultured under conditions that promote ciliogenesis, such as serum starvation in MDCK cells. Anti-OFD1 antibodies (particularly those targeting the C-terminus) can be used in conjunction with ciliary markers like acetylated α-tubulin, which specifically stains the ciliary axoneme . This dual labeling approach allows clear distinction between OFD1's basal body localization and the ciliary axoneme.

For nuclear localization studies, counterstaining with DAPI or other nuclear markers is essential to confirm the nuclear compartmentalization of OFD1. Biochemical fractionation of nuclear and cytosolic compartments followed by Western blot analysis provides complementary evidence of OFD1's dual localization pattern .

How can researchers effectively study OFD1 self-association and protein partner interactions?

OFD1 protein demonstrates the ability to self-associate as well as interact with other protein partners like RuvBl1. Multiple complementary approaches are recommended for comprehensive interaction studies:

• Yeast two-hybrid screening: This approach has successfully identified OFD1 protein partners, including RuvBl1. Using full-length OFD1 as bait against cDNA libraries (e.g., HeLa library) can reveal potential interactors that can then be validated through other methods .

• Co-immunoprecipitation: For validating OFD1 self-association, co-transfection of differently tagged OFD1 constructs (e.g., MycGFP-OFD1 and Flag-OFD1) followed by immunoprecipitation with one tag and detection with the other has proven effective . For studying interactions with endogenous proteins, immunoprecipitation of OFD1 followed by immunoblotting for the partner protein provides evidence of physiological interactions .

• Domain mapping: Structure-function analysis using truncated OFD1 constructs can identify specific domains mediating interactions. For instance, the coiled-coil rich region of OFD1 has been demonstrated to mediate its self-association properties .

• Proximity ligation assays: While not specifically mentioned in the search results, this technique provides spatial resolution of protein interactions and could complement traditional biochemical approaches for studying OFD1 associations.

What is the significance of the OFD1-RuvBl1 interaction and how can it be studied?

The interaction between OFD1 and RuvBl1 represents a significant finding with implications for understanding ciliary biology and disease mechanisms. RuvBl1 belongs to the AAA+-family of ATPases and has been linked to both cystic kidney development in zebrafish and ciliary assembly/function in Chlamydomonas reinhardtii . Given OFD1's role in ciliopathies and cystic kidney disease, this interaction may reveal mechanisms connecting nuclear functions with ciliary processes.

To study this interaction effectively:

• Co-immunoprecipitation validation: Researchers have demonstrated the OFD1-RuvBl1 interaction by immunoprecipitating endogenous OFD1 and detecting HA-tagged or MycGFP-tagged RuvBl1 in the immunoprecipitates . The reciprocal approach—immunoprecipitating tagged RuvBl1 and detecting endogenous OFD1—has also confirmed this interaction .

• Endogenous interaction verification: To establish physiological relevance, immunoprecipitation of endogenous OFD1 followed by detection of endogenous RuvBl1 provides critical evidence. This approach requires antibodies specific to both proteins and may benefit from peptide elution strategies to minimize background .

• Molecular context analysis: The OFD1-RuvBl1 interaction occurs within a broader molecular context including components of the TIP60 histone acetyltransferase complex . Studying these associations may require sequential immunoprecipitation approaches or mass spectrometry-based analyses of OFD1 immunoprecipitates.

How should researchers interpret multiple bands in OFD1 Western blots?

Western blot analysis of OFD1 protein frequently reveals multiple bands, which can complicate data interpretation. There are several biological and technical explanations for these patterns:

• Isoform detection: OFD1 has up to three reported isoforms in humans, which can manifest as multiple bands in Western blot analysis . The apparent molecular weight of these bands may differ from the predicted weight (116.7 kDa for the canonical form) due to post-translational modifications or the intrinsic properties of the protein.

• Proteolytic processing: Some researchers have observed doublet bands in OFD1 immunoblots, which may reflect alternative spliced forms of the protein . This pattern has been documented in protein extracts from mouse embryos, suggesting developmental regulation of OFD1 isoform expression.

• Cross-reactivity: Non-specific antibody binding can produce additional bands. Proper controls, including peptide competition assays or OFD1 knockdown/knockout samples, can help distinguish specific from non-specific signals.

• Post-translational modifications: Phosphorylation, ubiquitination, or other modifications can alter OFD1's electrophoretic mobility, resulting in additional or shifted bands.

When interpreting OFD1 Western blots, researchers should consider these factors and include appropriate controls to validate band identity.

What are common challenges in OFD1 antibody-based experiments and how can they be addressed?

Researchers working with OFD1 antibodies may encounter several challenges that require specific troubleshooting approaches:

• Weak nuclear signal in immunofluorescence: The nuclear localization of OFD1 can be challenging to detect compared to its centrosomal/basal body signal . Optimization strategies include:

  • Using antibodies specifically validated for nuclear OFD1 detection

  • Optimizing fixation methods (paraformaldehyde vs. methanol)

  • Employing antigen retrieval techniques

  • Using confocal microscopy for improved signal resolution

• Distinguishing specific bands in co-immunoprecipitation: When studying interactions between OFD1 and proteins of similar molecular weight to antibody heavy chains (approximately 50 kDa, like RuvBl1), the heavy chain signal can mask the protein of interest . Solutions include:

  • Using tagged versions of the interacting protein that shift its molecular weight (e.g., MycGFP-RuvBl1 at ~80 kDa instead of ~50 kDa)

  • Employing HRP-conjugated protein A/G instead of secondary antibodies

  • Using light-chain specific secondary antibodies

• Background in immunoprecipitation experiments: High background can complicate the interpretation of OFD1 interaction studies. Strategies to address this include:

  • Specific peptide elution (e.g., using the OFD1 peptide KVESLTGFSHEELDDSW)

  • Increasing wash stringency

  • Pre-clearing lysates with protein A/G beads before immunoprecipitation

  • Using crosslinking approaches to stabilize antibody-bead interactions

What cell and tissue types are most appropriate for studying OFD1 functions?

The choice of experimental system significantly impacts OFD1 studies, with certain models offering distinct advantages:

• MDCK cells: These epithelial cells readily form primary cilia under serum starvation conditions, making them excellent for studying OFD1's role in ciliogenesis and its localization to basal bodies .

• Cos-7 cells: These cells have been successfully used for overexpression and co-immunoprecipitation studies of OFD1 and its interacting partners . Their large cytoplasm and efficient transfection properties make them suitable for visualizing protein localizations.

• HeLa cells: This cell line has been employed for studying OFD1's nuclear functions and for generating cDNA libraries for interaction screens .

• Kidney tissues: Given OFD1's association with cystic kidney disease, renal tissues represent physiologically relevant models for studying its function in disease contexts .

• Developmental model systems: OFD1 gene orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken, offering diverse models for studying its evolutionary conservation and developmental roles .

The experimental question should guide the choice of model system, with ciliated cell types being particularly valuable for studying OFD1's centrosomal and ciliary functions.

What controls should be included when validating a new anti-OFD1 antibody?

Rigorous validation of anti-OFD1 antibodies is essential for experimental reliability. Recommended controls include:

• Preimmune serum comparison: Comparing staining patterns between the anti-OFD1 antibody and its corresponding preimmune serum can help identify specific versus non-specific signals . This is particularly important for immunofluorescence studies of nuclear OFD1.

• Peptide competition assays: Preincubating the antibody with the immunizing peptide (e.g., KVESLTGFSHEELDDSW for anti-OFD1 Cter or RTNRLIEDERKNKEK for anti-OFD1 cent) should abolish specific signals .

• Multiple antibody comparison: Using antibodies recognizing different epitopes of OFD1 (such as anti-OFD1 Cter and anti-OFD1 cent) can confirm signal specificity—concordant results with different antibodies increase confidence in specificity .

• OFD1 knockdown/knockout validation: Demonstrating reduced or absent signal in cells depleted of OFD1 (via siRNA, shRNA, or CRISPR/Cas9) provides compelling evidence of antibody specificity.

• Overexpression controls: Detection of overexpressed OFD1 (wild-type or tagged versions) can confirm the antibody's ability to recognize the protein of interest, particularly important for antibodies used in Western blot applications.

What are the optimal dilutions and conditions for using anti-OFD1 antibodies in different applications?

The optimal working conditions for anti-OFD1 antibodies vary by application and specific antibody preparation:

For anti-OFD1 Cter and anti-OFD1 cent antibodies specifically, purification by affinity chromatography with protein A-Sepharose matrix has been recommended prior to use .

When performing Western blot analysis after immunoprecipitation experiments, anti-OFD1 antibodies have been used at higher dilutions (approximately 1:500) to minimize background signal .

How do commercially available OFD1 antibodies differ in terms of their epitope recognition and applications?

Commercial anti-OFD1 antibodies target different regions of the protein, which can impact their performance in specific applications:

• C-terminal targeting antibodies: Similar to the anti-OFD1 Cter described in the literature (epitope: residues 996-1011), these antibodies recognize the C-terminal region of OFD1 . These have proven effective for detecting OFD1 at basal bodies and in biochemical applications like Western blotting and immunoprecipitation.

• Central region antibodies: Comparable to the anti-OFD1 cent (epitope: residues 351-364), these target the middle portion of the protein . These may detect different OFD1 conformations or provide complementary detection to C-terminal antibodies.

Commercial antibodies are available in various formats, including:

• Unconjugated primary antibodies (most common)

• Biotin-conjugated for amplification systems

• Directly labeled with fluorophores (Cy3, DyLight488, etc.)

• Enzyme-conjugated versions for direct detection

Selection among these options should be guided by the specific application requirements and researcher preference.

How are OFD1 antibodies being used to advance understanding of ciliopathies?

OFD1 antibodies have become instrumental tools in ciliopathy research, helping elucidate the molecular mechanisms underlying these disorders:

• Protein interaction networks: Immunoprecipitation with anti-OFD1 antibodies has revealed interactions with proteins like RuvBl1 and components of the TIP60 complex, suggesting potential mechanistic links between nuclear functions and ciliary processes disrupted in disease .

• Dual localization studies: The discovery of OFD1's presence at both basal bodies and within nuclei, facilitated by specific antibodies, has expanded understanding of how mutations in a single protein can cause pleiotropic developmental defects .

• Functional domains characterization: Anti-OFD1 antibodies have helped map the protein's functional regions, including the coiled-coil rich region that mediates self-association—information critical for understanding how specific mutations affect protein function .

• Developmental expression patterns: Immunohistochemistry with OFD1 antibodies has enabled researchers to track the protein's expression across tissues and developmental stages, providing insights into when and where OFD1 dysfunction might impact organogenesis.

These applications continue to evolve as researchers develop more sophisticated approaches to studying ciliary biology and disease mechanisms.

What emerging techniques are enhancing OFD1 protein research beyond traditional antibody applications?

While antibody-based methods remain foundational, several emerging techniques are complementing traditional approaches in OFD1 research:

• CRISPR/Cas9 genome editing: Creation of OFD1 knockout or knock-in cell lines and animal models provides powerful systems for studying protein function and validating antibody specificity.

• Proximity labeling approaches: Techniques like BioID or APEX2 fused to OFD1 enable identification of proteins in close spatial proximity to OFD1 in living cells, potentially revealing transient or context-specific interactions missed by co-immunoprecipitation.

• Super-resolution microscopy: Methods like STED, STORM, or SIM provide nanoscale resolution of OFD1 localization at centrosomes and basal bodies, offering unprecedented detail about its spatial organization.

• Mass spectrometry-based proteomics: Quantitative proteomic analysis of OFD1 interactomes, post-translational modifications, and expression levels across developmental stages or disease states provides systems-level insights into OFD1 biology.

• Patient-derived cellular models: iPSC-derived cells from patients with OFD1 mutations offer physiologically relevant systems for studying disease mechanisms and potential therapeutic approaches, with antibodies serving as critical tools for phenotypic characterization.

These advanced approaches, used in conjunction with well-validated antibodies, continue to expand our understanding of OFD1's complex biological functions and disease associations.